https://www.pharmaradar360.com/article/8d8c391caf92f7f3PharmaRadar360en2026-04-12T14:10:11.000ZGSK plans five Phase 3 studies for gynecological cancer ADC from Hansohhttps://www.pharmaradar360.com/article/d10b0fa4924d152fPharmaRadar360en2026-04-12T12:00:00.000ZGSK presents positive data for B7-H4-targeted ADC in gynaecological cancershttps://www.pharmaradar360.com/article/6539ba502e680f06PharmaRadar360en2026-04-12T11:15:00.000ZAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026https://www.pharmaradar360.com/article/373c555256c6877dPharmaRadar360en2026-04-12T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/d1a373feda7ea5c5PharmaRadar360en2026-04-12T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/3f9a008b849674c3PharmaRadar360en2026-04-12T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/98a4ffcafc501525PharmaRadar360en2026-04-12T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/54b3ddb463fd6279PharmaRadar360en2026-04-12T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/e36c00dee6cf475bPharmaRadar360en2026-04-12T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/d2f1ccdf8d0a027bPharmaRadar360en2026-04-12T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/29dd91c54cd7349fPharmaRadar360en2026-04-12T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/6adfb0918cd690dcPharmaRadar360en2026-04-12T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/ca3fac33b27ffd47PharmaRadar360en2026-04-12T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c0f64ef5d8bd5a54PharmaRadar360en2026-04-12T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/ea15404d12afcbb1PharmaRadar360en2026-04-12T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/75326695606f7de3PharmaRadar360en2026-04-12T00:00:00.000Z6203https://www.pharmaradar360.com/article/0515a85ec3e843fePharmaRadar360en2026-04-12T00:00:00.000ZHome page